21 patients in limbo as talks on funding life-saving drug Respreza break down

Irish patients are set to lose access to life-saving lung disease drug Respreza.

Talks on funding Respreza have collapsed between the HSE and CSL Behring, the pharmaceutical company which makes it.

Twenty-one people suffering from a genetic lung disease called Alpha 1 have been using it for more than 11 years.

They were told last Friday that they will lose access to a vital drug called Respreeza at the end of the month.

Patient Gerry Finnerty from Kinsealy in North Dublin, who is 59, said: "Nobody knows what's going to happen to (us).

"There's no drug there even to ease you off - there's just a striaght trap door: 'There: it's done'."

In a statement last week CSL Behring said: “We remain committed to AATD research to improve the quality of life of people living with the condition. Based on this commitment, we are currently in discussion with health authorities in both the US and Europe to finalise a randomised, non-placebo controlled study design which seeks to demonstrate the long-term safety and efficacy of Respreeza.

“CSL Behring is evaluating clinical sites in Ireland which may then be offered the opportunity to recruit severe AATD patients.”


More in this Section

Ibrahim Halawa released from prison in Egypt

WRC talks between trade unions and Irish Rail end without agreement

Taoiseach: Banks have dragged their heels too long over tracker scandal

Sinn Féin's former assembly member Caitriona Ruane quits Stormont role


Today's Stories

Bail for man, 60, accused of sexually assaulting four women in Cork

HSE to explain why it paid 600% drug price rise

River Lee’s first new bridge in decade installed

Drink driver caught for 11th time is jailed

Lifestyle

Why a good breakfast is a must for your kids

Facing fears while terrifying punters at Cork's Nightmare Realm

Weathering the storm of 1961: We watched 30 large trees uprooted

Remembering the dead: Poignant reason behind Cork’s Zombie Walk

More From The Irish Examiner